- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 6, 2024
Deals
MorphoSys’ long run ends with €2.7B Novartis takeout
Shift to product-focused company positioned German biotech for deal giving former Constellation assets to Swiss pharma
BioCentury | Nov 20, 2023
Regulation
Nov. 20 Quick Takes: Mixed myelofibrosis results from MorphoSys’ pelabresib
Plus: Regulatory delay for BMS, 2seventy’s Abecma, and updates from AstraZeneca and Ibiome
BioCentury | Mar 11, 2023
Emerging Company Profile
Opna Bio: targeting FMRP to treat cancer
Company’s other five small molecules come from CEO Gideon Bollag’s former company, Plexxikon
BioCentury | Mar 4, 2023
Regulation
March 3 Quick Takes: Praxis aims to start Phase III essential tremor study despite Phase II miss
Plus: Incyte stopping Jakafi myelofibrosis combo study and updates from Exelixis, Sangamo, BMS, Veru
BioCentury | Jan 6, 2023
Product Development
Kornowski shifts gears at Boston Pharma, sets NASH program as top priority
Ex-Roche exec refines focus, decides what to keep and commercialize vs. what to partner out
BioCentury | Dec 3, 2021
Distillery Therapeutics
Computational identification of cancer compounds for PAH
BioCentury | Dec 10, 2019
Clinical News
Dec. 9 ASH Quick Takes: Kite, Principia, Blueprint, Precision and Rocket
BioCentury | Nov 7, 2019
Clinical News
Constellation heading for pivotal myelofibrosis trial as ASH data lifts shares
BioCentury | Jun 1, 2019
Product Development
ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts
BioCentury’s analysis of ASCO 2019 abstracts shows bispecifics outpacing CAR Ts in solid tumors
Items per page:
1 - 10 of 55